And the company, which backed onto the Nasdaq in August 2017 through its merger with Galena Biopharma, is considering another reverse merger too. All of that said, the company gave no timeline for it to make its decision and cautioned in a statement that it may not even pursue any of the options up for consideration. "We are committed to identifying a strategic plan which will enhance shareholder value while allowing for the acceleration of our development programs, so that our novel immunotherapeutics, GPS [galinpepimut-S] and NPS [nelipepimut-S], may benefit cancer patients," said Sellas CEO Angelos Stergiou, M.D., Sc.D., in the statement. RELATED: Sellas snags Nasdaq listing in reverse merger with Galena Sellas recently kicked off a phase 1/2 combination trial of GPS with Merck's Keytruda, the company said. It is testing the combo in patients with acute myeloid leukemia (AML), as well as those with ovarian cancer, triple-negative breast cancer, small-cell lung cancer and colorectal cancer.